Class I: Sodium Channel Blockers

Core Concepts

The target: fast sodium channels and phase 0

In working cardiac muscle and Purkinje fibers, the action potential begins when sodium channels snap open and sodium floods in — phase 0. The maximum rate of rise of phase 0 (how steeply the cell depolarizes) determines how fast the impulse travels. Class I drugs plug these sodium channels, slowing phase 0 and therefore slowing conduction. They also make cells less excitable: a stronger stimulus is needed to trigger firing, and abnormal automaticity is suppressed. Because ventricular muscle and Purkinje fibers are the main tissues using fast sodium channels, Class I drugs act primarily on the ventricles — which is why they are most associated with ventricular dysrhythmias.

The subclasses: Ia, Ib, and Ic

The three subclasses differ in how strongly and how quickly they bind the sodium channel:

• Class Ia (e.g., quinidine, procainamide, disopyramide): moderate sodium blockade, plus potassium channel blockade that lengthens repolarization. The combined effect slows conduction and prolongs the action potential (prolonged QT). Used for both atrial and ventricular dysrhythmias.
• Class Ib (e.g., lidocaine, mexiletine): fast on-off binding that preferentially blocks sodium channels in depolarized, rapidly firing tissue — exactly the state of tissue in an ischemic or tachycardic ventricle. Little effect on normal tissue at normal rates. This "use dependence" makes Ib drugs the classic choice for ventricular dysrhythmias, especially with acute ischemia.
• Class Ic (e.g., flecainide, propafenone): the most potent sodium blockade, markedly slowing conduction with little effect on repolarization. Their strong proarrhythmic potential in certain patient groups (notably structural heart disease) has been well documented, and they are generally reserved for specific supraventricular dysrhythmias in carefully selected patients.

Use dependence: why rate matters

All Class I drugs show use dependence — they block more channels when the tissue is firing rapidly. Think of it as the drug "crowding" channels that open frequently. A drug that binds and unbinds slowly (Ic) accumulates more block at any rate, while a fast binder (Ib) can clear between beats and so affects only very rapid or abnormal tissue. This is why the same dose can be well tolerated at a normal rate yet produce toxicity when the heart speeds up — and why lidocaine can suppress ventricular ectopy during ischemia without measurably slowing a normal rhythm.

The proarrhythmia problem

Every Class I drug can worsen or create dysrhythmias. The classic pattern is excessive conduction slowing: if phase 0 is suppressed too much, the impulse crawls through the ventricle, QRS widens, and the stage is set for re-entry — the drug can convert a stable rhythm into an unstable one. This risk is why the Cardiac Arrhythmia Suppression Trial (CAST) findings are taught in every pharmacology course: drugs that suppressed premature beats actually increased mortality in people with structural heart disease. The lesson is not about one drug — it is that suppressing ectopy on the monitor is not the same as helping the patient, and that patient selection matters enormously.

Nursing monitoring logic

Mechanism predicts what the nurse watches for:

• QRS width — widened QRS signals slowed ventricular conduction, the signature of Class I effect/toxicity.
• QT interval — prolonged by Class Ia (potassium channel effect); a very long QT raises torsades risk.
• New ectopy or worsening rhythm — proarrhythmia can look like more premature beats, not fewer.
• Electrolytes — low potassium exaggerates sodium-channel and repolarization problems; potassium and magnesium abnormalities should be identified and corrected (per provider orders) before these drugs are expected to work safely.
• Symptoms — lightheadedness, syncope, or palpitations may reflect hemodynamic consequences of a drug-induced rhythm change.

Verify the specific drug, dose, monitoring schedule, and laboratory parameters against the current formulary and prescriber's orders; administration and monitoring scope varies by jurisdiction and facility.

Common Confusions